This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu

A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05577715
Recruitment Status : Recruiting
First Posted : October 13, 2022
Last Update Posted : July 18, 2023
Eisai Inc.
Information provided by (Responsible Party):
Bristol-Myers Squibb

Brief Summary:
The aim of this study is to characterize the safety and tolerability of MORAb-202, and to assess the objective response rate in participants with previously treated, metastatic NSCLC AC.

Condition or disease Intervention/treatment Phase
Carcinoma, Non-Small-Cell Lung Drug: MORAb-202 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Open-label, Randomized Study of MORAb-202 (Farletuzumab Ecteribulin), a Folate Receptor Alpha-targeting Antibody-Drug Conjugate, in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies
Actual Study Start Date : November 14, 2022
Estimated Primary Completion Date : March 4, 2024
Estimated Study Completion Date : February 28, 2026

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: MORAb-202 Drug: MORAb-202
Specified dose on specified days
Other Names:
  • Farletuzumab Ecteribulin
  • BMS-986445

Primary Outcome Measures :
  1. Incidence of treatment-related adverse events (TRAEs) leading to study treatment discontinuation [ Time Frame: Up to 2 years ]
  2. Objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 per investigator assessment [ Time Frame: Up to 2 years ]

Secondary Outcome Measures :
  1. Number of participants with adverse events (AEs) [ Time Frame: Up to 2 years ]
  2. Number of participants with serious adverse events (SAEs) [ Time Frame: Up to 2 years ]
  3. Number of participants with treatment related AEs and SAEs [ Time Frame: Up to 2 years ]
  4. Number of participants with AEs of special interest (AESI) [ Time Frame: Up to 2 years ]
  5. Number of deaths [ Time Frame: Up to 2 years ]
  6. Number of participants with clinical laboratory abnormalities [ Time Frame: Up to 2 years ]
  7. Progression-free Survival (PFS) by RECIST 1.1 per investigator assessment [ Time Frame: Up to 2 years ]
  8. Disease Control Rate (DCR) by RECIST 1.1 per investigator assessment [ Time Frame: Up to 2 years ]
  9. Duration of Response (DoR) by RECIST 1.1 per investigator assessment [ Time Frame: Up to 2 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically documented metastatic NSCLC AC (as defined by the 8th International Association for the Study of Lung Cancer Classification).
  • Measurable target disease assessed by the investigator according to RECIST 1.1.
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1

Exclusion Criteria:

  • NSCLC histologies other than AC (ie, squamous cell carcinoma, large cell carcinoma).
  • Significant third-space fluid retention (eg, ascites or pleural effusion) that requires repeated drainage.
  • Prior pneumonectomy. Prior lobectomy and segmentectomy are allowed > 12 months before treatment.
  • Recent chest radiotherapy. Participants with chest or chest wall radiation may be permitted if chest radiation is documented > 6 months before starting study treatment.

Other protocol-defined inclusion/exclusion criteria apply.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT05577715

Layout table for location contacts
Contact: BMS Study Connect Contact Center 855-907-3286
Contact: First line of the email MUST contain the NCT# and Site #.

Show Show 33 study locations
Sponsors and Collaborators
Bristol-Myers Squibb
Eisai Inc.
Layout table for investigator information
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
Additional Information:
Layout table for additonal information
Responsible Party: Bristol-Myers Squibb Identifier: NCT05577715    
Other Study ID Numbers: CA116-003
2022-000131-23 ( EudraCT Number )
MORAb-202-G000-203 ( Other Identifier: Eisai Protocol Number )
First Posted: October 13, 2022    Key Record Dates
Last Update Posted: July 18, 2023
Last Verified: July 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myers Squibb's data sharing policy and process can be found at:
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Clinical Study Report (CSR)
Time Frame: See Plan Description
Access Criteria: See Plan Description

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Bristol-Myers Squibb:
Farletuzumab ecteribulin
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Antineoplastic Agents